SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) (Frankfurt: XMPA) reports financial results for the quarter ended March 31, 2007.
“In the first quarter we continued to execute on our clinical development strategy by initiating our chronic ischemia trial and making preparations to start our heart attack and breast reconstruction trials,” said Christopher J. Calhoun, Chief Executive Officer for Cytori. “To support our 2008 product launch in Europe for reconstructive surgery, we started building out our Celution™ System commercialization and manufacturing infrastructure, which included the implementation and testing of our production capabilities and the signing of a key distributor relationship for Italy, Spain and Portugal.”
